Monday, August 31, 2015

FDA panel gives OK to Glaxo, Ligand drug

A Food and Drug Administration advisory panel unanimously voted to recommend approval of a blood-clotting drug being developed by GlaxoSmithKline and Ligand Pharmaceuticals.

FDA panel gives OK to Glaxo, Ligand drug


Surprise! A Food and Drug Administration advisory panel is backing approval for a blood-clotting drug being developed by GlaxoSmithKline and a San Diego firm.

The advisors voted unanimously today to recommend approval for Promacta to treat an immune system disorder. That's a bit of a surprise given that the FDA staff said the data indicated that the drug didn't work any better than a placebo in clinical testing.

After the staff report was released earlier in the week, the stock price of GlaxoSmithKline's development partner, Ligand Pharmaceuticals, plummeted to its lowest level in a decade. Today, Ligard shares popped up by more than 50 percent.

Shares of GlaxoSmithKline, which is a much bigger company, also rose on the action by the Oncologic Drugs Advisory Committee, rising little more than 1 percent.

The full FDA generally follows the recommendations of its advisory panels, but nothing requires it to do so. The key date for FDA action is June 19.

Inquirer Columnist
We encourage respectful comments but reserve the right to delete anything that doesn't contribute to an engaging dialogue.
Help us moderate this thread by flagging comments that violate our guidelines.

Comment policy: comments are intended to be civil, friendly conversations. Please treat other participants with respect and in a way that you would want to be treated. You are responsible for what you say. And please, stay on topic. If you see an objectionable post, please report it to us using the "Report Abuse" option.

Please note that comments are monitored by staff. We reserve the right at all times to remove any information or materials that are unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane, indecent or otherwise objectionable. Personal attacks, especially on other participants, are not permitted. We reserve the right to permanently block any user who violates these terms and conditions.

Additionally comments that are long, have multiple paragraph breaks, include code, or include hyperlinks may not be posted.

Read 0 comments
comments powered by Disqus
About this blog

Mike Armstrong Inquirer Columnist
Also on
letter icon Newsletter